AR012996A1 - Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador. - Google Patents

Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.

Info

Publication number
AR012996A1
AR012996A1 ARP980102881A ARP980102881A AR012996A1 AR 012996 A1 AR012996 A1 AR 012996A1 AR P980102881 A ARP980102881 A AR P980102881A AR P980102881 A ARP980102881 A AR P980102881A AR 012996 A1 AR012996 A1 AR 012996A1
Authority
AR
Argentina
Prior art keywords
sensitizer
preparation
pharmaceutical composition
insulin
medicinal product
Prior art date
Application number
ARP980102881A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR012996(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR012996A1 publication Critical patent/AR012996A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

Uso de un sensibilizador a la insulina para preapracion de un medicamento util para el tratamiento de diabetes mellitus y procesos asociados a ladiabetes mellitus en un mamífero, que comprende una cantidad eficaz no toxica y farmacéuticamenteefica z de un sensibilizador a la insulina y un secretagogo deinsulina a un mamífero con necesidad de ello y composicion farmacéutica que comprende dicho sensibilizador.
ARP980102881A 1997-06-18 1998-06-17 Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador. AR012996A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
AR012996A1 true AR012996A1 (es) 2000-11-22

Family

ID=26311744

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102879A AR008025A1 (es) 1997-06-18 1998-06-17 Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
ARP980102881A AR012996A1 (es) 1997-06-18 1998-06-17 Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102879A AR008025A1 (es) 1997-06-18 1998-06-17 Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina

Country Status (34)

Country Link
EP (3) EP2266576A1 (es)
JP (1) JP2001523270A (es)
KR (3) KR20080011356A (es)
CN (1) CN1168451C (es)
AP (1) AP1600A (es)
AR (2) AR008025A1 (es)
AT (1) ATE353654T1 (es)
AU (1) AU8539298A (es)
BG (2) BG109397A (es)
BR (1) BR9810142A (es)
CA (1) CA2294385C (es)
CO (1) CO4940457A1 (es)
CZ (1) CZ299310B6 (es)
DE (1) DE69837089T2 (es)
DZ (1) DZ2522A1 (es)
EA (1) EA003025B1 (es)
ES (1) ES2283064T3 (es)
HK (1) HK1028200A1 (es)
ID (1) ID24065A (es)
IL (1) IL133137A (es)
IN (1) IN189319B (es)
MA (1) MA24571A1 (es)
MY (1) MY125855A (es)
NO (3) NO326263B1 (es)
NZ (1) NZ501163A (es)
OA (1) OA11510A (es)
PE (1) PE108199A1 (es)
PL (2) PL198018B1 (es)
SK (1) SK286028B6 (es)
TR (1) TR199903096T2 (es)
TW (1) TW542717B (es)
UA (1) UA67743C2 (es)
UY (1) UY25048A1 (es)
WO (1) WO1998057649A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
CA2389237A1 (en) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
WO2005041962A1 (en) * 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
BRPI0620020A2 (pt) 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE10199003I1 (de) 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU650465B2 (en) 1990-07-03 1994-06-23 Yamanouchi Pharmaceutical Co., Ltd. Bisheterocyclic compound
AU645112B2 (en) 1990-08-23 1994-01-06 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
ATE202352T1 (de) 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
JPH07508747A (ja) 1992-07-03 1995-09-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 医薬用複素環化合物
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
OA11510A (en) 2004-02-03
IL133137A0 (en) 2001-03-19
EA200000039A1 (ru) 2000-08-28
MA24571A1 (fr) 1998-12-31
AP9901717A0 (en) 1999-12-31
SK286028B6 (sk) 2008-01-07
ATE353654T1 (de) 2007-03-15
AU8539298A (en) 1999-01-04
CN1168451C (zh) 2004-09-29
ID24065A (id) 2000-07-06
UA67743C2 (uk) 2004-07-15
EP0999845A1 (en) 2000-05-17
PL198018B1 (pl) 2008-05-30
NO996264L (no) 2000-02-17
TR199903096T2 (xx) 2000-08-21
UY25048A1 (es) 2000-09-29
EA003025B1 (ru) 2002-12-26
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
EP2266576A1 (en) 2010-12-29
CA2294385C (en) 2007-06-05
CO4940457A1 (es) 2000-07-24
BG109397A (bg) 2006-05-31
DZ2522A1 (fr) 2003-02-01
CZ9904577A3 (en) 2001-05-16
KR20080011356A (ko) 2008-02-01
NO326263B1 (no) 2008-10-27
EP1671637A3 (en) 2007-12-19
BG104058A (en) 2000-10-31
NO996264D0 (no) 1999-12-17
TW542717B (en) 2003-07-21
AP1600A (en) 2006-04-28
MY125855A (en) 2006-08-30
EP0999845B1 (en) 2007-02-14
BG64817B1 (bg) 2006-05-31
DE69837089T2 (de) 2007-06-21
CZ299310B6 (cs) 2008-06-18
SK179199A3 (en) 2000-11-07
PL337510A1 (en) 2000-08-28
NZ501163A (en) 2002-02-01
NO2009002I1 (no) 2009-03-02
CN1260719A (zh) 2000-07-19
BR9810142A (pt) 2000-08-08
ES2283064T3 (es) 2007-10-16
JP2001523270A (ja) 2001-11-20
HK1028200A1 (en) 2001-02-09
DE69837089D1 (de) 2007-03-29
EP1671637A2 (en) 2006-06-21
PE108199A1 (es) 2000-01-14
CA2294385A1 (en) 1998-12-23
KR20010013840A (ko) 2001-02-26
AR008025A1 (es) 1999-12-09
IN189319B (es) 2003-02-08
KR20070011651A (ko) 2007-01-24
IL133137A (en) 2004-02-08

Similar Documents

Publication Publication Date Title
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
FI944035A (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
WO2001000223A3 (en) Multiple agent diabetes therapy
AR025426A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para lapreparacion de medicamentos y formas de administracion que contienen esas sales
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
DK34687D0 (da) Laegemiddel til nasal anvendelse, dets fremstilling og anvendelse
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
AR016768A1 (es) COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
HRP20000781B1 (en) Effervescent preparations
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
ATE295169T1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
AR007058A1 (es) Uso de interferon en medicamentos y composiciones para contacto oromucosal
TR199901237T2 (xx) Bir tienilsiklohegzilamin t�revinin tedavide yeni uygulamas�.
ECSP993215A (es) Nueva composicion y uso
ECSP982593A (es) Nuevo metodo de tratamiento vi
DE59813300D1 (de) Pharmazeutische zubereitungen
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982535A (es) Nuevo metodo de tratamiento (i)

Legal Events

Date Code Title Description
FB Suspension of granting procedure